E
The startup develops synthetic cannabidiol and cannabigerol-based drug products for the treatment of inflammatory, autoimmune, and neurodegenerative diseases. By creating two families of new chemical entities, the company targets significant gaps in effective therapies for these conditions.
San Diego, United States
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops synthetic cannabidiol and cannabigerol-based drug products for the treatment of inflammatory, autoimmune, and neurodegenerative diseases. By creating two families of new chemical entities, the company targets significant gaps in effective therapies for these conditions.